Related Experiment Video
Updated: Jun 6, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
The Influence of Melanoma Extracellular Vesicles on Benign Melanocytes: A Role for PRAME in Modulation of the Tumor
Xiaochen Liu1, Ralf Janknecht2, Sepideh Nikki Asadbeigi1
1Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Department of Dermatology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Abstract:
Melanoma is an aggressive skin cancer with a high tendency for metastasis and resistance to conventional therapies. This study explores the role of preferentially expressed antigen in melanoma (PRAME), a cancer-testis antigen, in melanoma progression, focusing on its function in melanoma-derived extracellular vesicles (EVs) and its impact on benign melanocytes. We show that PRAME is highly expressed in melanoma cell lines, tissues, and patient plasma and is present in EVs. These EVs transfer PRAME protein and mRNA to benign melanocytes, leading to significant alterations in gene expression, increased cell proliferation, and a more malignant phenotype. Knockout of PRAME in melanoma cells reduces these protumorigenic effects on melanocytes, emphasizing PRAME's role in EV-mediated communication. The detection of PRAME in plasma EVs suggests its potential as a biomarker for monitoring disease progression and therapy response, including in rare melanoma subtypes. These findings highlight PRAME as a key player in melanoma progression and suggest targeting PRAME-containing EVs as a potential therapeutic strategy to inhibit melanoma progression and metastasis.
Insights
Preferentially expressed antigen in melanoma (PRAME) in extracellular vesicles promotes melanoma progression by altering benign melanocyte behavior. Targeting PRAME-loaded EVs may inhibit melanoma metastasis and improve therapy response.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Melanoma is an aggressive skin cancer known for metastasis and therapy resistance.
- Preferentially expressed antigen in melanoma (PRAME), a cancer-testis antigen, is implicated in tumor progression.
- Extracellular vesicles (EVs) mediate intercellular communication and play roles in cancer.
Purpose of the Study:
- To investigate the role of PRAME in melanoma progression.
- To determine PRAME's function within melanoma-derived EVs.
- To assess the impact of PRAME-carrying EVs on benign melanocytes.
Main Methods:
- Analysis of PRAME expression in melanoma cell lines, tissues, and patient plasma.
- Isolation and characterization of PRAME from melanoma EVs.
- Co-culture experiments with melanoma EVs and benign melanocytes.
- PRAME gene knockout in melanoma cells.
Main Results:
- PRAME is highly expressed in melanoma and detected in EVs.
- Melanoma EVs transfer PRAME (protein and mRNA) to benign melanocytes.
- PRAME transfer induces gene expression changes, increased proliferation, and malignant phenotype in melanocytes.
- PRAME knockout diminishes EV-mediated protumorigenic effects on melanocytes.
Conclusions:
- PRAME is actively secreted via EVs and drives melanoma progression.
- PRAME in EVs facilitates intercellular communication, promoting a malignant phenotype.
- Plasma EV-associated PRAME shows potential as a biomarker for melanoma monitoring.
- Targeting PRAME-containing EVs presents a novel therapeutic strategy against melanoma metastasis.
More Related Videos
Related Concept Videos
The Tumor Microenvironment
Abnormal Proliferation
Mitogens and the Cell Cycle

